High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity.
Intensive doses of carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support were given to four patients with advanced melanoma. Three developed clinically diagnosed, severe veno-occlusive liver disease, which was fatal in two cases. The dose of carboplatin (450 mg/m2) was comparable with that used in ambulatory regimens. At the doses and schedule employed, this three-drug combination produced excessive hepatic toxicity. Caution is suggested when giving carboplatin in combination with intensive doses of other chemotherapeutic agents with known hepatotoxic potential.
Bone Marrow Transplantation Program, Duke University Comprehensive Cancer Center, Durham, NC 27710.
R B
RB
Jones
E J
EJ
Shpall
M
M
Ross
D
D
Coniglio
M L
ML
Affronti
W P
WP
Peters
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use / Q000633:toxicity*; D016026:Bone Marrow Transplantation; D016190:Carboplatin; D002330:Carmustine / Q000008:administration & dosage / Q000633:toxicity; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000633:toxicity; D005260:Female; D006504:Hepatic Veno-Occlusive Disease / Q000139:chemically induced*; D006801:Humans; D008545:Melanoma / Q000188:drug therapy / Q000628:therapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000633:toxicity
D009944:Organoplatinum Compounds; D003520:Cyclophosphamide; D016190:Carboplatin; D002330:Carmustine